Form 4: Esperion Therapeutics CFO Benjamin Halladay Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Esperion Therapeutics' CFO, Benjamin Halladay, sold 8 shares of common stock on April 17, 2025, at a price of $0.964 per share to satisfy tax obligations related to vested restricted stock units.
Summary
- On April 17, 2025, Benjamin Halladay, the Chief Financial Officer of Esperion Therapeutics, Inc., sold 8 shares of the company's common stock.
- The transaction was executed at a price of $0.964 per share.
- Following the transaction, Halladay directly owns 481,702 shares of Esperion Therapeutics.
- The sale was conducted to cover tax obligations arising from the vesting of restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an insider stock sale for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This sale appears to be related to tax obligations, which is a common reason for such transactions.
Stakeholder Impact
- The sale of shares by an insider could have a minor negative impact on shareholder sentiment, although the reason for the sale (tax obligations) is generally understood.
Key Dates
| Date | Description |
|---|---|
| 2022/11/16 | Date of execution for the Limited Power of Attorney. |
| 2025/04/17 | Date of the transaction where Benjamin Halladay sold shares. |
| 2025/04/21 | Date of signature for the Form 4 filing. |
Keywords
Esperion Therapeutics, Benjamin Halladay, CFO, stock sale, Form 4, insider trading, tax obligations, restricted stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.